Ceapro Reports Third Quarter 2011 Financial Results
EDMONTON, ALBERTA -- (MARKET WIRE) -- 11/29/11 -- Ceapro Inc. (TSX VENTURE: CZO) ("Ceapro" or the Company") today announced its financial results for the three-month and nine-month periods ended September 30, 2011. These results are presented in accordance with the International Financial Reporting Standards (IFRS) of the International Accounting Standards Board (IASB).
Third quarter 2011 corporate highlights
-- Launch of a new website reflecting Ceapro's innovation and focus on the
personal care industry.
-- Signing of a technical sales and distribution agreement with California
based Ross Organic Specialty Sales to represent Ceapro's all natural
line of products in the Western United States.
-- Advancement in planning for the expansion of Ceapro's manufacturing
capabilities.
Subsequent to quarter-end
-- Appointment of Grant Thornton LLP as Ceapro's auditors as the partners
and employees Stout & Company LLP have joined Grant Thornton.
FINANCIAL RESULTS FOR THE THIRD QUARTER AND THE FIRST NINE MONTHS ENDED SEPTEMBER 30, 2011
Revenues were $1,515,000 for the three-month period ended September 30, 2011, as compared to $1,708,000 for the same period in 2010. For the first nine months, revenues were $4,234,000 in 2011 compared to $3,881,000 for the same period in 2010. This increase of sales of 9% in 2011 is attributed to higher sales volumes of avenanthramides, beta glucan and oat oil.
Research and development Investments were $$339,000 and $755,000 for the three-month period and nine-month period ended September 30, 2011 as compared to $236,000 and $513,000 for the same periods in 2010. These respective increases of 44% ($103,000) and 47% ($242,000) reflect our strong commitment to expand our pipeline and position Ceapro as a highly recognized innovative Company.
Net income/loss. For the third quarter of 2011, net loss was $108,000 versus a net profit of $98,000 for the same period in 2010. This loss is equal to the increase in R&D during the period. For the first nine-months of 2011, Net income amounted to $323,000 compared to $290,000 for the same period in 2010 which included the recovery of a one time cost of $315,000.
"While we are building a solid scientific portfolio for Ceapro and expanding our partnership network, we are very pleased with our year to date 2011 results showing profitability and continuous improvement in our balance sheet" said Gilles Gagnon, Acting CEO. As previously announced, the third quarter of 2011 clearly demonstrates that Ceapro's commitment to growth is rooted in strong innovation and robust science as evidenced by the significant increase of investments in our Research and Development program" he added.
The complete financial statements are available for review on SEDAR at http://sedar.com/Ceapro and on the Company's website at www.ceapro.com .
About Ceapro Inc.
Ceapro Inc. is a Canadian growth-stage biotechnology company. Primary business activities relate to the development and commercialization of active ingredients for personal care and cosmetic industries using proprietary technology and natural, renewable resources. To learn more about Ceapro, visit www.ceapro.com.
CEAPRO INC.
Consolidated Statements of Net Income (Loss) and Comprehensive Income
(Loss)
Unaudited
Quarters Ended September Nine Months Ended
30, September 30,
2011 2010 2011 2010
$ $ $ $
-------------------------------------------------------------------------
Revenue (note 19) 1,515,096 1,708,071 4,234,179 3,881,414
Cost of goods sold 886,681 962,001 1,903,748 2,207,896
-------------------------------------------------------------------------
Gross margin 628,415 746,070 2,330,431 1,673,518
Research and product
development 339,244 235,846 754,918 513,244
General and
administration 323,911 335,654 993,167 960,748
Sales and marketing 21,116 10,759 85,226 49,875
Other operating loss
(note 14) 7,878 14,477 31,975 4,124
Write off of property and
equipment - - 10,490
-------------------------------------------------------------------------
Income (loss) from
operations (63,734) 149,334 465,145 135,037
Finance costs (note 15) (44,088) (51,042) (142,492) (159,579)
SGGF legal fees (note
17b) - - - 314,983
-------------------------------------------------------------------------
Income (loss) before tax (107,822) 98,292 322,653 290,441
Income taxes
Current 5,000 28,000 197,000 87,000
Reduction as a result of
applying non-capital
losses carried forward
against the current
period's taxable income (5,000) (28,000) (197,000) (87,000)
-------------------------------------------------------------------------
Net income (loss) and
comprehensive income
(loss) for the period (107,822) 98,292 322,653 290,441
-------------------------------------------------------------------------
Net income (loss) per
common share:
-------------------------------------------------------------------------
Basic (0.00) 0.00 0.01 0.01
-------------------------------------------------------------------------
Diluted (0.00) 0.00 0.01 0.01
-------------------------------------------------------------------------
Weighted average number
of common shares
outstanding 56,578,948 54,421,094 56,555,638 52,623,671
-------------------------------------------------------------------------
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Contacts: Ceapro Inc. Branko Jankovic Vice President and CFO 780.917.8376 bjankovic@ceapro.com www.ceapro.com
Source: Ceapro Inc.
Released November 29, 2011